Ertapenem use and antimicrobial resistance to group 2 carbapenems in Gram-negative infections: a systematic review

References

• Falagas ME, Peppas G, Makris GC, Karageorgopoulos DE, Matthaiou DK. Meta-analysis: ertapenem for complicated intra-abdominal infections. Aliment. Pharmacol. Ther. 27(10), 919–931 (2008).
   PubMed Web of Science ®Google Scholar
• Goff DA, Mangino JE. Ertapenem: no effect on aerobic Gram-negative susceptibilities to imipenem. J. Infect. 57(2), 123–127 (2008).
   PubMed Web of Science ®Google Scholar
• Beovic B, Kreft S, Seme K, Cizman M. Does ertepenem alter the susceptibility of Pseudomonas aeruginosa to carbapenems? J. Chemother. 23(4), 216–220 (2011).
   PubMed Web of Science ®Google Scholar
• Jeon MH, Choi SH, Kwak YG et al. Risk factors for the acquisition of carbapenem-resistant Escherichia coli among hospitalized patients. Diagn. Microbiol. Infect. Dis. 62(4), 402–406 (2008).
   PubMedGoogle Scholar
• Patel G, Huprikar S, Factor SH, Jenkins SG, Calfee DP. Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies. Infect. Control Hosp. Epidemiol. 29(12), 1099–1106 (2008).
   PubMed Web of Science ®Google Scholar
• Sheng WH, Liao CH, Lauderdale TL et al. A multicenter study of risk factors and outcome of hospitalized patients with infections due to carbapenem-resistant Acinetobacter baumannii. Int. J. Infect. Dis. 14(9), e764–e769 (2010).
   PubMed Web of Science ®Google Scholar
• Chang HJ, Hsu PC, Yang CC et al. Risk factors and outcomes of carbapenem-nonsusceptible Escherichia coli bacteremia: a matched case–control study. J. Microbiol. Immunol. Infect. 44(2), 125–130 (2011).
   PubMedGoogle Scholar
• Patel N, Harrington S, Dihmess A et al. Clinical epidemiology of carbapenem-intermediate or -resistant Enterobacteriaceae. J. Antimicrob. Chemother. 66(7), 1600–1608 (2011).
   PubMed Web of Science ®Google Scholar
• Rosmarakis ES, Soteriades ES, Vergidis PI, Kasiakou SK, Falagas ME. From conference abstract to full paper: differences between data presented in conferences and journals. FASEB J. 19(7), 673–680 (2005).
   PubMed Web of Science ®Google Scholar
• Cook PP, Gooch M, Rizzo S. Reduction in fluoroquinolone use following introduction of ertapenem into a hospital formulary is associated with improvement in susceptibility of Pseudomonas aeruginosa to group 2 carbapenems: a 10-year study. Antimicrob. Agents Chemother. 55(12), 5597–5601 (2011).
   PubMed Web of Science ®Google Scholar
• Eagye KJ, Nicolau DP. Fluoroquinolone use is not associated with the change in imipenem susceptibility of Pseudomonas aeruginosa in 25 hospitals. Adv. Ther. 28(4), 326–333 (2011).
   PubMedGoogle Scholar
• Goldstein EJ, Citron DM, Peraino V, Elgourt T, Meibohm AR, Lu S. Introduction of ertapenem into a hospital formulary: effect on antimicrobial usage and improved in vitro susceptibility of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 53(12), 5122–5126 (2009).
   PubMed Web of Science ®Google Scholar
• Graber CJ, Hutchings C, Dong F, Lee W, Chung JK, Tran T. Changes in antibiotic usage and susceptibility in nosocomial Enterobacteriaceae and Pseudomonas isolates following the introduction of ertapenem to hospital formulary. Epidemiol. Infect. 140(1), 115–125 (2012).
   PubMedGoogle Scholar
• Lima AL, Oliveira PR, Paula AP et al. Carbapenem stewardship: positive impact on hospital ecology. Braz. J. Infect. Dis. 15(1), 1–5 (2011).
   PubMed Web of Science ®Google Scholar
• Pires dos Santos R, Jacoby T, Pires Machado D et al. Hand hygiene, and not ertapenem use, contributed to reduction of carbapenem-resistant Pseudomonas aeruginosa rates. Infect. Control Hosp. Epidemiol. 32(6), 584–590 (2011).
   PubMedGoogle Scholar
• dos Santos RP, Jacoby T, Goldani LZ. Antimicrobial stewardship lessons: do Pseudomonas-sparing agents, such as ertapenem, effectively improve bacterial resistance? Antimicrob. Agents Chemother. 54(7), 3076; author reply 3076–3076; author reply 3077 (2010).
   Google Scholar
• Nicolau DP, Carmeli Y, Crank CW et al. Carbapenem stewardship: does ertapenem affect Pseudomonas susceptibility to other carbapenems? A review of the evidence. Int. J. Antimicrob. Agents 39(1), 11–15 (2012).
   PubMed Web of Science ®Google Scholar
• Matthaiou DK, Michalopoulos A, Rafailidis PI et al. Risk factors associated with the isolation of colistin-resistant Gram-negative bacteria: a matched case–control study. Crit. Care Med. 36(3), 807–811 (2008).
   PubMed Web of Science ®Google Scholar
• Teo J, Cai Y, Tang S et al. Risk factors, molecular epidemiology and outcomes of ertapenem-resistant, carbapenem-susceptible Enterobacteriaceae: a case–case–control study. PLoS ONE 7(3), e34254 (2012).
   PubMed Web of Science ®Google Scholar